Further to intimation dated October 23, 2023 and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations', Lincoln Pharmaceuticals has informed that the Board of Directors of the Company at its meeting held today, on Thursday, November 02, 2023, have considered and approved the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2023 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter and half year ended on September 30, 2023. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, it enclosed financial highlights for the aforesaid quarter. The Meeting of the Board of Directors of the Company commenced at 10:45 AM and concluded at 12:15 pm.
The above information is a part of company’s filings submitted to BSE.